# Trade Mark Journal No.2026/013 27 March 2026

## WO0000001898193 (40,42)

Office of origin: United States of America

Date of International Registration:17 December 2025
Date of designation in the UK: 17 December 2025

International priority date claimed: 17 November 2025 (United States of America) (99501527)

Class 40
  Custom manufacture of reformulated pharmaceuticals for easier patient delivery; custom manufacturing, processing, and treating the therapeutic molecules of others; biomanufacturing for others, namely, manufacturing therapeutic molecules of others using biological organisms in the manufacturing process; custom manufacture of reformulated pharmaceuticals and therapeutics.
Class 42
  Research and development in the field of pharmaceuticals and drug delivery; scientific and medical research, namely, conducting clinical trials for others; scientific research and design and development, namely, product design and development in the field of excipients and formulations for use with therapeutic biologics; scientific research and design, namely product design and development in the field of therapeutic formulation development; consulting in the fields of product design and development in the field of therapeutic formulation and excipient development; chemical engineering in the nature of formulation and reformulation of therapeutic compositions; development of new technology for others in the field of biomaterials, biotechnology and nanotechnology.

Halozyme, Inc.

Representative: Morgan, Lewis & Bockius UK LLP, Condor House, 5-10 St. Paul's Churchyard London EC4M 8AL UNITED KINGDOM